Pediatrics Doctors in Cooperstown, NY Accepting Medicare

7 Pediatrics doctors found. Showing 1 - 7

Dr. Chris L Kjolhede, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3290    Fax: 607-547-5605

Dr. William Charles Wassel, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3074    Fax: 607-547-6782

Dr. Margaret Ruth Young, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-7980    Fax: 607-547-6782

Dr. Anne Marie Gadomski, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3909    Fax: 607-547-6325

Kelly Elizabeth Dewey, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3456

Brandon Greene, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-7980    Fax: 607-547-6782

Kerri K Leblanc, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Atwell Rd, Cooperstown, NY 13326 Phone: 607-547-3290    Fax: 607-547-5605

News Archive

CEO Roundtable on Cancer's Life Sciences Consortium initiates Project Data Sphere

The CEO Roundtable on Cancer's Life Sciences Consortium has initiated Project Data Sphere, a collaborative effort to create a shared platform where clinical trials data will become available to researchers for further studies that will speed cancer research.

New UBC study reveals public attitudes toward under-vaccinated children and their parents

Mothers are viewed negatively if their child hasn't been vaccinated, no matter the reason. But mothers who outright refuse to vaccinate their children are viewed in a harsher light compared to those who delay vaccines because of safety concerns or who aren't up to date due to time constraints.

PharmAthene prices registered public offering

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has priced a registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.

Atorvastatin could prove an effective therapy for multiple sclerosis

Scientists at the University of California, San Francisco and Stanford University Medical Center are reporting compelling new evidence that the cholesterol-lowering drug atorvastatin could prove an effective therapy for preventing the progression of, and reversing the severity of, multiple sclerosis (MS).

Read more Medical News

› Verified 1 days ago